DE60136174D1 - Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren - Google Patents

Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren

Info

Publication number
DE60136174D1
DE60136174D1 DE60136174T DE60136174T DE60136174D1 DE 60136174 D1 DE60136174 D1 DE 60136174D1 DE 60136174 T DE60136174 T DE 60136174T DE 60136174 T DE60136174 T DE 60136174T DE 60136174 D1 DE60136174 D1 DE 60136174D1
Authority
DE
Germany
Prior art keywords
human monoclonal
rabiesvirus
nucleic acids
monoclonal antibodies
related methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60136174T
Other languages
German (de)
English (en)
Inventor
Douglas C Hooper
Bernhard Dietzschold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Application granted granted Critical
Publication of DE60136174D1 publication Critical patent/DE60136174D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60136174T 2000-05-16 2001-05-04 Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren Expired - Lifetime DE60136174D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20451800P 2000-05-16 2000-05-16
PCT/US2001/014468 WO2001088132A2 (en) 2000-05-16 2001-05-04 Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods

Publications (1)

Publication Number Publication Date
DE60136174D1 true DE60136174D1 (de) 2008-11-27

Family

ID=22758233

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60136174T Expired - Lifetime DE60136174D1 (de) 2000-05-16 2001-05-04 Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren

Country Status (9)

Country Link
US (1) US6890532B2 (https=)
EP (1) EP1282703B1 (https=)
JP (1) JP4819285B2 (https=)
AT (1) ATE411387T1 (https=)
CA (1) CA2419148C (https=)
DE (1) DE60136174D1 (https=)
IL (1) IL152825A (https=)
RU (1) RU2272809C2 (https=)
WO (1) WO2001088132A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040013672A1 (en) * 2000-05-16 2004-01-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
AU2001281151A1 (en) * 2000-08-24 2002-03-04 Thomas Jefferson University Rhabdovirus-based vectors to express high levels of functional human antibodies
WO2003016501A2 (en) * 2001-08-21 2003-02-27 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
WO2004106375A1 (en) * 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
RS53239B (sr) 2005-02-02 2014-08-29 University Of Massachusetts Humana antitela protiv besnila i njihove upotrebe
JP2008263964A (ja) * 2007-03-29 2008-11-06 Yamaguchi Univ コウモリ由来細胞株
JP2010085126A (ja) * 2008-09-29 2010-04-15 Adtec Kk 狂犬病ウイルス中和抗体価判定具および狂犬病ウイルス中和抗体価の測定方法
KR101388680B1 (ko) * 2011-03-18 2014-04-28 (주)셀트리온 광견병 바이러스를 중화시킬 수 있는 결합 분자
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
RU2533802C1 (ru) * 2013-08-30 2014-11-20 федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Тримеризованное однодоменное антитело, специфически связывающееся с гликопротеином g вируса бешенства, нейтрализующее вирус бешенства
WO2019227039A1 (en) * 2018-05-24 2019-11-28 Lankenau Institute For Medical Research Compositions comprising antibodies to rabies virus and the uses thereof
CN111166877A (zh) * 2019-12-30 2020-05-19 西安回天血液制品有限责任公司 一种狂犬病人免疫球蛋白的制备方法
CN114958774B (zh) * 2022-05-08 2023-10-27 中国医学科学院医学生物学研究所 抗狂犬病病毒单克隆抗体及分泌该抗体的杂交瘤细胞株与应用
CN119431525B (zh) * 2024-10-08 2025-04-11 北京溯本源和生物科技有限公司 狂犬病毒g蛋白重组抗原、单克隆抗体及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
IL89857A0 (en) * 1988-04-07 1989-12-15 Erba Carlo Spa Human monoclonal antibodies specifically recognizing rabies virus hybridoma,cells producing them,pharmaceutical compositions containing them and their production
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ES2070172T3 (es) 1988-04-16 1995-06-01 Celltech Ltd Procedimiento para producir proteinas mediante adn recombinante.
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies

Also Published As

Publication number Publication date
US6890532B2 (en) 2005-05-10
ATE411387T1 (de) 2008-10-15
CA2419148C (en) 2011-07-12
EP1282703A2 (en) 2003-02-12
WO2001088132A2 (en) 2001-11-22
IL152825A0 (en) 2003-06-24
EP1282703B1 (en) 2008-10-15
RU2272809C2 (ru) 2006-03-27
US20030165507A1 (en) 2003-09-04
CA2419148A1 (en) 2001-11-22
JP4819285B2 (ja) 2011-11-24
WO2001088132A3 (en) 2002-07-18
IL152825A (en) 2009-07-20
JP2004528803A (ja) 2004-09-24

Similar Documents

Publication Publication Date Title
DE60136174D1 (de) Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
ATA1302001A (de) Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
ATE395930T1 (de) Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
NO20051345L (no) Humane anti-IFN-gamma noytraliserende antistoffer som selektive IFN-gamma reaksjonsvei inhibitorer
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
TR200300478T2 (tr) Hümanize antiLT-ß-R antikorları
CA2469833A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
HRP20110893T1 (hr) Postupci liječenja upalnih bolesti pomoću specifičnih tvari za vezanje humanog angiopoetina-2
DE60137631D1 (de) Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen
ATE288502T1 (de) Gezieltes antikörper-verfahren
WO2003039470A3 (en) Polyvalent immunogen of hiv
EP1499328A4 (en) METHOD FOR TREATING NEKROTIZING ENTEROCOLITIS
EP1530579A4 (en) RECOMBINANT ANTIBODIES AND COMPOSITIONS AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP1487480A4 (en) HYBRID MOLECULES AND METHODS FOR TREATING IMMUNE DISEASES
PE20050962A1 (es) Anticuerpos completamente humanos contra 4-1bb humano
SE0302312D0 (sv) Peptide-based passive immunization therapy for treatment of atherosclerosis
DE60231475D1 (de) Materialien und methoden zur behandlung von hepatitis c
DE69005908D1 (de) Monoklonale Antikörper zur Behandlung nach einem Kontakt mit Tollwutvirus.
CY1105549T1 (el) Καινουργια μεθοδος θεραπειας
EA200200927A1 (ru) Способ профилактики и лечения заболеваний иммунной системы и средство для его осуществления
ATE440616T1 (de) Verfahren zur steigerung der antigenimmunogenität
ATE135013T1 (de) Verfahren zur erhöhung der rate der modifikation metastabiler bindungen

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: MURGITROYD & COMPANY, 48149 MUENSTER

8364 No opposition during term of opposition